MedRing for Overactive Bladder
Overactive Bladder (OAB)
Pre-clinical/Early ClinicalActive
Key Facts
About LiGalli
LiGalli is an early-stage biotech innovator developing an intelligent, connected intravaginal ring (the MedRing) for personalized drug delivery and health monitoring. The company's platform technology combines a physical device, a smartphone companion app, and a cloud data platform to enable precise dosing, improve patient compliance, and collect valuable health data. Initially targeting conditions like overactive bladder, LiGalli is positioning itself at the intersection of women's health, digital therapeutics, and smart medical devices, with a vision to create more tailored and effective treatments.
View full company profileTherapeutic Areas
Other Overactive Bladder (OAB) Drugs
| Drug | Company | Phase |
|---|---|---|
| NiNA | EBT Medical | Pre-clinical |
| Weekly Microneedle Patch for Overactive Bladder | TSRL Inc | Pre-clinical |
| Overactive Bladder Program | Evestra | Pre-clinical/Clinical |